Objective: The frequency of epileptic seizures is high in patients with brain tumors and its treatment is important. It is atypical mitotic proliferation that is effective in the proliferation of malignant tumor cells. It is known that antiepileptics have direct or indirect effects on mitotic proliferation. In our study, we aimed to maximize the use of both the antiepileptic effect and the cytoreductive effect by suppressing tumor growth while choosing the drug to stop the seizure. Methods: In our study, anti-tumoral activities of antiepileptic agents containing gabapentin, pregabalin, valproic acid, levetiracetam, zonisamide, phenytoin, carbamazepine in in vitro glioblastoma (c6) and neuroblastoma cell cultures (NA/An1) were evaluated with a real-time cell analysis system. Statistically, the difference between groups was investigated by analysis of variance, followed by post hoc Tukey's test Statistical Package for the Social Sciences software 16.0 (IBM Inc, Chicago, IL, USA). Results: In our study, it was observed that all drugs except gabapentin had antimitotic effects in glioblastoma cell cultures, among which phenytoin, levetiracetam, and valproic acid had dose-dependent antimitotic effects, while carbamazepine had reduced antimitotic effects at concentrations above 25 mu g/mL. In in vitro neuroblastoma cell cultures, it was found that only valproic acid and zonisamide had antimitotic effects, and other drugs studied did not have antimitotic effects. Conclusions: In our study, it was observed that the preference of antiepileptics with a high antimitotic effect on tumoral cells was important when arranging seizure treatment in patients with brain tumors.

Background Some patients with neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSD) have similar clinical features do not have Anti-Aquaporin-4 (AQP4) antibody and may have a different condition with different outcomes with regard to motor disability Objectives To determine whether the AQP4 antibody has a relationship with the prognosis of transverse myelitis in terms of motor disability Methods Sera of 34 patients with NMO (n=27) and NMOSD with isolated or recurrent myelitis (n=7) were all investigated for the presence of AQP4 antibody by a cell-based indirect immunofluorescence assay (IIFA). The prognostic values of anti-AQP4 antibody were evaluated in terms of a good motor prognosis (able to walk unaided for at least 100 metres) and a poor motor prognosis (with aid to walk at least 100 metres or a worse condition). Results In our study, the anti-AQP4 antibody9s seropositivity in all cases was 61.8[percnt] (n=21), was 59.3[percnt] in NMO and 71.4[percnt] in NMOSD cases. Anti-AQP4 antibody seropositivites had older disease onset (39±13.5 vs 27.9±8.7, p=0.009). And 33.3[percnt] of the seropositive patients and 38.5[percnt] of the seronegative patients had a poor motor disability, during a follow-up period of 102±79.1 months. There was no significant difference that existed between anti-AQP4 antibody seropositivity and seronegative in terms of motor disability (p=0.770). Conclusions As compared with anti-AQP4 antibody-negative ones, anti-AQP4 antibody-positive patients show significantly older disease onset. The outcome of myelitis in terms of motor disability was similar in both anti-AQP4 antibody-positive and negative patients. Disclosure: Dr. Idiman has nothing to disclose. Dr. Idiman has nothing to disclose. Dr. Kaya has nothing to disclose. Dr. Cevik has nothing to disclose. Dr. Altun has nothing to disclose. Dr. Mehdiyev has nothing to disclose.

Background:The presence of oligoclonal bands (OCBs) in cerebrospinal fluid (CSF) of multiple sclerosis (MS) is now well established to support the clinical diagnosis. On the other hand,a monoclonal response can represent the initial stage of an oligoclonal response, before the other antibody clones become visible. Objectives:To evaluate the presence of an isolated CSF monoclonal immunoglobulin(Ig) band and to analyse the clinical and radiological diagnosis of those samples with a single Ig band. Methods:3524 CSF samples using agarose gel isoelectric focusing (IEF) were re-examined and those with an isolated CSF monoclonal Ig band were detected. Results:In 1.4[percnt] a monoclonal band in CSF was detected. 27.5[percnt] of them were diagnosed clinically isolated syndrome (CIS),49[percnt] relapsing remitting multiple sclerosis (RRMS) according to Poser criteria, 11.8[percnt] secondary progressive MS (SPMS),and 2[percnt] radiologically isolated syndrome (RIS). There was no primary progressive MS (PPMS) patient. The mean disease duration and the mean EDSS score of MS patients including CIS and RIS patients were 59.8±71.4 months and 2.6±1.8 respectively. 69[percnt] of them met all the Barhoff criteria. The remaining was diagnosed other inflammatory neurological diseases (OIND) (9.8[percnt]) (1p with chronic inflammatory demyelinating polyneuropathy, 1pt with neuromyelitis optica, 1pt with paraneoplastic syndrome, 2pts with acute disseminated encephalomyelitis). Conclusions:The presence of an isolated CSF monoclonal Ig band is rare. Although most of the samples were diagnosed as MS according to both clinical and paraclinical (MRI) parameters, they had only a single Ig band in CSF. Not only OCBs, but also an isolated CSF monoclonal band might be a cornerstone for the diagnosis of MS at least for some patients. On the other hand, single CSF band is an indication for repeating a CSF analysis, unless other criteria clearly point to a diagnosis of MS,and to consider an alternative diagnosis. Patients with an isolated CSF monoclonal band need careful consideration.

Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease with which a variety of neuropathic disorders have been associated. Among these, the acute inflammatory demyelinating polyradiculoneuropathy variant of Guillain–Barré syndrome has been well established. However, acute axonal lumbosacral polyradiculoneuropathy accompanied by albuminocytological dissociation in the cerebrospinal fluid has been extremely rarely reported in SLE. We report on a 47-year-old woman with discoid lupus presenting with acute onset of flaccid paraplegia. Extensive investigations suggested the diagnoses of axonal lumbosacral polyradiculoneuropathy and SLE. Treatment with intravenous methylprednisolone and cyclophosphamide resulted in clinical recovery. Development of immune-mediated polyneuropathy in a patient with discoid lupus should forewarn the clinician regarding transformation into the systemic form of the disease.